This study looked at what happens to infants with prenatal substance exposure when they leave the hospital—and, importantly, who they are discharged to. Researchers analyzed data from 1,808 birthing parent–infant pairs who had documented prenatal opioid exposure or were assessed for Neonatal Opioid Withdrawal Syndrome (NOWS). They examined the types of substances involved, the severity of infant withdrawal, whether the parent was receiving medication for opioid use disorder (MOUD), and other factors that influenced discharge decisions.
Study Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11973236/pdf/nihms-2045628.pdf
The findings highlight how complicated the circumstances surrounding prenatal opioid exposure can be. Infants exposed to multiple substances, methamphetamine/amphetamine, cannabis, or opioids did not all have the same experiences after birth. The type and severity of exposure mattered, but so did treatment and support for the parent. In particular, the researchers found that parent engagement in treatment—including MOUD—may be a protective factor for keeping families together after birth.
Narrative Overview of the Results:
The researchers identified four patterns of substance exposure among the 1,808 families: a poly-use group, a methamphetamine/amphetamine group, a cannabis group, and a prescription-opioid group. The prescription-opioid group was the largest, representing 974 infants (54%), followed by the poly-use group (355; 20%), cannabis group (275; 15%), and methamphetamine/amphetamine group (204; 11%).
A major finding was that infants with prenatal exposure to multiple substances, methamphetamine/amphetamines, or opioids had a lower likelihood of leaving the hospital with their parent(s). In the poly-use and methamphetamine/amphetamine groups, less than half—approximately 47%–49%—were discharged to their parent(s). The researchers also found that greater severity of infant withdrawal, measured in part by whether medication was needed to treat withdrawal, influenced placement decisions in some groups.
At the same time, the study identified an important protective factor: parent participation in treatment for opioid use disorder, particularly MOUD, was associated with a greater likelihood of discharge to the birthing parent(s) in the prescription-opioid group. This finding reinforces the importance of supporting pregnant people in treatment rather than viewing substance exposure only through a child-safety lens.
The study does not tell us that a particular discharge arrangement produces better long-term outcomes. The authors specifically note that future research needs to follow these children to understand how different placements affect developmental and psychosocial outcomes.
Bullet Point Summary:
The study included 1,808 birthing parent–infant pairs with documented prenatal opioid exposure or NOWS assessment.
Researchers identified four major exposure patterns:
54% prescription-opioid exposure
20% poly-substance exposure
15% cannabis exposure
11% methamphetamine/amphetamine exposure
Infants exposed to multiple substances, methamphetamine/amphetamines, or opioids were less likely to be discharged to their parent(s).
In the poly-use and methamphetamine/amphetamine groups, only about 47%–49% of infants were discharged to their parent(s).
Severity of infant withdrawal mattered. When infants required medication to treat withdrawal symptoms, this was associated with discharge decisions in the poly-use and prescription-opioid groups.
Treatment engagement mattered, too. Among parents in the prescription-opioid group, prenatal participation in MOUD was associated with a greater likelihood of discharge to the birthing parent(s).
The study highlights that substance exposure, infant withdrawal, parental treatment, and social circumstances interact. A positive toxicology result or NOWS diagnosis does not tell the whole story of a family.
The researchers emphasize that more work is needed to understand the mechanisms behind these decisions and, importantly, which discharge arrangements lead to the best short- and long-term outcomes for children and families.
What This Means for You:
If you are raising a child with prenatal opioid exposure, this study highlights something important: what happens after birth matters.
A baby's prenatal exposure or experience with Neonatal Opioid Withdrawal Syndrome (NOWS) can influence the decisions made in the hospital, but those decisions are also shaped by many other factors. The research shows that parent treatment and engagement can be an important source of stability and support.
For caregivers, this means:
Your child's early history is more complicated than a diagnosis or toxicology result.
The severity of withdrawal can affect what happens immediately after birth, but it does not determine your child's future.
Treatment and support for parents are also support for children. Helping a parent access and remain engaged in treatment can strengthen the family and may help keep parent and child together.
Families affected by opioid use disorder need support, not judgment. Stigma and fear can make it harder for parents to seek the help they need.
If a child is separated from a parent after birth, that experience becomes part of the child's early environment and deserves thoughtful, trauma-informed consideration.
If you are a foster or adoptive parent, you do not need to know everything about your child’s prenatal history to support them well. What matters most is getting to know this child—their strengths, patterns, sensitivities, and what helps them feel safe and regulated.
Stability and responsive caregiving matter. A safe, predictable, supportive relationship can help children build regulation skills and thrive. When a child is struggling, think about the underlying need rather than assuming the behavior is intentional defiance.
Your observations matter. Foster and adoptive parents may be among the first to recognize patterns in sleep, sensory processing, emotional regulation, attention, feeding, or development as a child grows. Understanding these patterns can help caregivers respond with connection, predictability, and appropriate support.
Most importantly, your child is more than their prenatal history or their placement history. Children with prenatal opioid exposure have individual strengths, personalities, and needs. With understanding, stability, and supportive relationships, they can thrive.